SCHEDULE: T. Rowe Price Discloses 11% Stake in Tenax Therapeutics

T. Rowe Price Associates, Inc. has reported a beneficial ownership of 11.0% in Tenax Therapeutics Inc., holding 2,841,114 shares of common stock as of April 30, 2026.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G, indicating it beneficially owns 2,841,114 shares of Tenax Therapeutics Inc. common stock.
• This represents 11.0% of the total class of securities.
• The filing is an amendment (Amendment No. 2) to a previous filing.
• T. Rowe Price Associates, Inc. acts as an investment adviser for various clients, including the T. Rowe Price Health Sciences Fund, which holds a significant portion of these shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a significant stake by a major investor is positive, the explicit denial of beneficial ownership for control purposes tempers the bullish sentiment.

Positives

• T. Rowe Price Associates, Inc., a significant institutional investor, has disclosed a substantial stake in Tenax Therapeutics, potentially signaling confidence in the company's prospects.
• The T. Rowe Price Health Sciences Fund holds 9.2% of the class, indicating focused investment within the healthcare sector.

Negatives

• The filing explicitly denies beneficial ownership for the purpose of influencing control, which could be interpreted as a neutral or cautious stance rather than strong endorsement.

Risks

• The ultimate power to direct dividends and sale proceeds rests with the individual and institutional clients, not solely with T. Rowe Price Associates, Inc., introducing a layer of indirect control.
• Any discretionary authority delegated to T. Rowe Price Associates, Inc. can be revoked at any time by its clients.

Future Outlook

The filing does not contain forward-looking statements or guidance from Tenax Therapeutics Inc. It solely reports on the ownership stake of T. Rowe Price Associates, Inc.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that significant Schedule 13G filings by major asset managers like T. Rowe Price often indicate a substantial investment thesis, potentially influencing market perception and attracting further investor interest in the biotechnology and therapeutics sector.

Stakeholder Impact

• Shareholders: The increased visibility from a major institutional investor like T. Rowe Price may positively influence investor sentiment and potentially the stock price.
• T. Rowe Price Clients: The T. Rowe Price Health Sciences Fund and other clients benefit from the investment management services provided by T. Rowe Price Associates, Inc. in acquiring and holding these securities.

Next Steps

• T. Rowe Price Associates, Inc. will continue to manage investment portfolios for its clients, including the T. Rowe Price Health Sciences Fund, which holds these shares.
• Tenax Therapeutics Inc. will continue its business operations, subject to the oversight of its management and board.

Key Dates

Recommendation

The filing indicates a significant passive investment by a major institutional player, which is generally a positive signal. However, the explicit denial of beneficial ownership for control purposes suggests a lack of active engagement or intent to influence the company's strategic direction. Therefore, a 'hold' recommendation is appropriate, pending further information on Tenax Therapeutics' operational performance and strategic initiatives.

Keywords

Tenax Therapeutics, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, Healthcare Fund